Current and next generation influenza vaccines: Formulation and production strategies PC Soema, R Kompier, JP Amorij, GFA Kersten European Journal of Pharmaceutics and Biopharmaceutics 94, 251-263, 2015 | 358 | 2015 |
Development of stable influenza vaccine powder formulations: challenges and possibilities JP Amorij, A Huckriede, J Wilschut, HW Frijlink, WLJ Hinrichs Pharmaceutical research 25, 1256-1273, 2008 | 269 | 2008 |
A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation V Saluja, JP Amorij, JC Kapteyn, AH De Boer, HW Frijlink, WLJ Hinrichs Journal of Controlled Release 144 (2), 127-133, 2010 | 243 | 2010 |
Buccal and sublingual vaccine delivery H Kraan, H Vrieling, C Czerkinsky, W Jiskoot, G Kersten, JP Amorij Journal of controlled release 190, 580-592, 2014 | 219 | 2014 |
Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses … JP Amorij, V Saluja, AH Petersen, WLJ Hinrichs, A Huckriede, HW Frijlink Vaccine 25 (52), 8707-8717, 2007 | 214 | 2007 |
Needle-free influenza vaccination JP Amorij, WLJ Hinrichs, HW Frijlink, JC Wilschut, A Huckriede The Lancet infectious diseases 10 (10), 699-711, 2010 | 157 | 2010 |
Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach PC Soema, GJ Willems, W Jiskoot, JP Amorij, GF Kersten European journal of pharmaceutics and biopharmaceutics 94, 427-435, 2015 | 149 | 2015 |
Towards tailored vaccine delivery: needs, challenges and perspectives JP Amorij, GFA Kersten, V Saluja, WF Tonnis, WLJ Hinrichs, B Slütter, ... Journal of Controlled Release 161 (2), 363-376, 2012 | 146 | 2012 |
Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying JP Amorij, J Meulenaar, WLJ Hinrichs, T Stegmann, A Huckriede, ... Vaccine 25 (35), 6447-6457, 2007 | 143 | 2007 |
Developments in the formulation and delivery of spray dried vaccines G Kanojia, R Have, PC Soema, H Frijlink, JP Amorij, G Kersten Human vaccines & immunotherapeutics 13 (10), 2364-2378, 2017 | 87 | 2017 |
Pulmonary vaccine delivery: a realistic approach? WF Tonnis, GF Kersten, HW Frijlink, WLJ Hinrichs, AH de Boer, JP Amorij Journal of aerosol medicine and pulmonary drug delivery 25 (5), 249-260, 2012 | 84 | 2012 |
A design of experiment approach to predict product and process parameters for a spray dried influenza vaccine G Kanojia, GJ Willems, HW Frijlink, GFA Kersten, PC Soema, JP Amorij International journal of pharmaceutics 511 (2), 1098-1111, 2016 | 83 | 2016 |
Influenza vaccine manufacturing: effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes TC Kon, A Onu, L Berbecila, E Lupulescu, A Ghiorgisor, GF Kersten, ... PloS one 11 (3), e0150700, 2016 | 80 | 2016 |
Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures F Geeraedts, V Saluja, W ter Veer, JP Amorij, HW Frijlink, J Wilschut, ... The AAPS journal 12, 215-222, 2010 | 79 | 2010 |
Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars WF Tonnis, JP Amorij, MA Vreeman, HW Frijlink, GF Kersten, ... European Journal of Pharmaceutical Sciences 55, 36-45, 2014 | 76 | 2014 |
Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics M Tafaghodi, V Saluja, GFA Kersten, H Kraan, B Slütter, JP Amorij, ... Vaccine 30 (36), 5341-5348, 2012 | 74 | 2012 |
Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant V Saluja, JP Amorij, ML van Roosmalen, K Leenhouts, A Huckriede, ... The AAPS journal 12, 109-116, 2010 | 74 | 2010 |
Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage J de Jonge, JP Amorij, WLJ Hinrichs, J Wilschut, A Huckriede, HW Frijlink european journal of pharmaceutical sciences 32 (1), 33-44, 2007 | 71 | 2007 |
Development of cross-protective influenza A vaccines based on cellular responses PC Soema, E van Riet, G Kersten, JP Amorij Frontiers in immunology 6, 237, 2015 | 55 | 2015 |
Development of thermostable lyophilized inactivated polio vaccine H Kraan, P van Herpen, G Kersten, JP Amorij Pharmaceutical research 31, 2618-2629, 2014 | 52 | 2014 |